PureCN peptide info@purecnpeptide.com

PureCN Peptide Explores GHK-Cu Copper Peptide and Its Potential Beyond Skin Rejuvenation From Skin Health to Tissue Repair and Healthy Aging: Understanding the Science Behind GHK-Cu GHK-Cu, commonly known as copper peptide, has attracted growing attention in skincare, regenerative research, and the broader conversation about healthy aging. While it is often associated with cosmetic products designed to improve skin appearance, scientific interest in GHK-Cu extends far beyond its potential skincare applications. Research has explored its possible involvement in collagen production, tissue repair, blood vessel formation, antioxidant activity, inflammation regulation, and neurological health. These findings have raised an important question: Could GHK-Cu have a broader role in supporting the body's natural repair and maintenance processes? PureCN Peptide examines the science behind this small but biologically interesting peptide, including its discovery, proposed mechanisms, potential...

  BREAKING: U.S. Opens the Door to Six Popular Peptides — BPC-157, TB-500, MOTS-c and More Enter a New Regulatory Era Major Policy Shift Creates New Opportunities for Peptide Compounding in the United States, Raising Expectations for Greater Access, Manufacturing Standards, and Medical Oversight WASHINGTON, October 28, 2026 — The U.S. peptide industry is entering a significant new chapter following a major federal policy development involving six widely discussed experimental peptides. The announcement, discussed by Dr. Alex Tatem in a recent industry update, has attracted considerable attention from researchers, healthcare professionals, fitness enthusiasts, and the broader wellness community. The policy, advanced by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., introduces an interim enforcement-discretion approach that allows licensed pharmacies and physicians to compound six specific peptides under defined conditions without facing FDA enforcement action. The ...